AstraZeneca reported positive Phase 3 results for an Imfinzi and Imdelltra maintenance regimen in extensive-stage small cell lung cancer and won FDA accelerated approval for Etcamah with a CDK4/6 inhibitor in ESR1-mutated HR-positive, HER2-negative metastatic breast cancer. The Etcamah regimen cut the risk of progression or death by 56% in the SERENA-6 trial and delivered median progression-free survival of 16.0 months, versus 9.2 months with standard care. The company also released full Phase 3 data showing tozorakimab reduced moderate and severe COPD exacerbations by 30% and 29% across the overall study populations in OBERON and TITANIA, respectively. The FDA accepted the biologic's license application under Priority Review, with an action date anticipated in the first quarter of 2027. AstraZeneca shares were down 0.74% at $161.49 on Tuesday.